This prospective, multicenter, open-label, single arm, clinical trial enrolled postmenopausal breast cancer patients (n = 45) with elevated CRP and taking predominantly aromatase inhibitors, to receive a combination of HT, omega-3 fatty acids, and curcumin for 1 month. The gene discussed is CYP19A1; the disease is breast carcinoma.